Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain

Effort Is Built On Decades Of Sodium Channel Research

Executive Summary

Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.

You may also be interested in...

Lilly Doubles Down On Novel Pain Drugs With Confo Therapeutics Deal

Belgium’s Confo Therapeutics gains its first big pharma partner in the field of non-opioid pain treatment, giving the big pharma will test its master protocol approach as it put its R&D muscle behind this major area of unmet need.

Vertex Readies For Commercial Future For Multi-Therapeutic Area R&D Strategy

Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.

Vertex Diabetes Cell Therapy Back On Track After FDA ‘Hiccup’

The US firm has received the FDA thumbs-up to continue a trial for its novel cell therapy candidate, VX-880, after what was perceived in some circles as an over-cautious decision by the regulator to pause the study in March.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts